Bashers only discuss share price...They can't talk about fundamentals because they're so good!
Revenues skyrocketed in one year.
Covid testing poised to surge as travelling resumes this summer. Corporate clients taken on.
Aristotle launched into a market with a severe cancer-testing backlog!
Company expands its reach internationally and functionally.
Moving into the lucrative and growing telemedecine market.
Q1 financials due in May.
AGM scheduled to closely follow, a clearly confident indicator.
Yet all bashers talk about is share price, and make wildly low predictions. Time to get in and strap on for the ride!
GLTA longs!